Gerardo Gómez-Moreno1, Antonio Aguilar-Salvatierra2, Esther Fernández-Cejas3, Rafael Arcesio Delgado-Ruiz4, Aleksa Markovic5, José Luis Calvo-Guirado6. 1. Department of Special Care in Dentistry, Pharmacological Research in Dentistry, Director of Master in Periodontology and Implant Dentistry, Faculty of Dentistry, University of Granada, Granada, Spain. 2. Department of Pharmacological Research in Dentistry, Faculty of Dentistry, University of Granada, Granada, Spain. 3. Department of Pharmacological Research in Dentistry Group, Faculty of Dentistry, University of Granada, Granada, Spain. 4. School of Dental Medicine, Stony Brook University, Stony Brook, NY, USA. 5. Department of Clinic of Oral Surgery, Faculty of Stomatology, University of Belgrade, Belgrade, Serbia. 6. International Research Cathedra UCAM, Universidad Católica San Antonio, Murcia, Spain.
Abstract
OBJECTIVES: The aim of this study was to evaluate the incidence of bleeding complications after dental implant placement in patients in treatment by the anticoagulant oral rivaroxaban without interrupting its administration or modifying dosage. MATERIALS AND METHODS: About 57 patients were divided into two groups: 18 had been in treatment by rivaroxaban for over 6 month before implant surgery and a control group consisted of 39 healthy subjects. All subjects received dental implants in different positions, without interrupting or modifying rivaroxaban dosage. Patients were treated in an outpatient setting. Non-absorbable sutures were used, and all patients were given gauze impregnated with tranexamic acid 5%, to bite on for 30-60 min. RESULTS: One rivaroxaban patient presented moderate bleeding the day after surgery, and two control patients presented moderate bleeding the day after and on the second day. Bleeding was managed with gauzes impregnated with tranexamic acid. No statistically significant differences (P = 0.688) were found in relation to bleeding episodes between the groups, with a relative risk = 0.919 based on the pooled groups and 95% confidence interval of 0.078-10.844. CONCLUSIONS: Dental implant surgery in patients taking the anticoagulant oral rivaroxaban can be performed safely in outpatients departments applying local hemostatic measures without the need to modify or interrupt anticoagulant medication.
OBJECTIVES: The aim of this study was to evaluate the incidence of bleeding complications after dental implant placement in patients in treatment by the anticoagulant oral rivaroxaban without interrupting its administration or modifying dosage. MATERIALS AND METHODS: About 57 patients were divided into two groups: 18 had been in treatment by rivaroxaban for over 6 month before implant surgery and a control group consisted of 39 healthy subjects. All subjects received dental implants in different positions, without interrupting or modifying rivaroxaban dosage. Patients were treated in an outpatient setting. Non-absorbable sutures were used, and all patients were given gauze impregnated with tranexamic acid 5%, to bite on for 30-60 min. RESULTS: One rivaroxabanpatient presented moderate bleeding the day after surgery, and two control patients presented moderate bleeding the day after and on the second day. Bleeding was managed with gauzes impregnated with tranexamic acid. No statistically significant differences (P = 0.688) were found in relation to bleeding episodes between the groups, with a relative risk = 0.919 based on the pooled groups and 95% confidence interval of 0.078-10.844. CONCLUSIONS: Dental implant surgery in patients taking the anticoagulant oral rivaroxaban can be performed safely in outpatients departments applying local hemostatic measures without the need to modify or interrupt anticoagulant medication.
Authors: Henning Hanken; Alexander Gröbe; Max Heiland; Ralf Smeets; Lan Kluwe; Johannes Wikner; Robert Koehnke; Ahmed Al-Dam; Wolfgang Eichhorn Journal: Clin Oral Investig Date: 2015-10-26 Impact factor: 3.573
Authors: Guido Galletti; Fortunato Alfonsi; Angelo Raffaele; Nicola Alberto Valente; Sibylle Chatelain; Roni Kolerman; Chiara Cinquini; Stefano Romeggio; Giovanna Iezzi; Antonio Barone Journal: Int J Environ Res Public Health Date: 2020-06-26 Impact factor: 3.390